Clinical Trial Update: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on OT-101 in combination with mFOLFIRINOX for advanced, unresectable, or metastatic pancreatic ductal adenocarcinoma; the Phase 2/3 study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OT-101 (OT-101)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Oncotelic Inc. | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING